EXHIBIT 3

COVINGTON & BURLING LLP

1201 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004-2401
TEL 202.662.6000
FAX 202.662.6291
WWW.COV.COM

BEIJING
BRUSSELS
LONDON
NEW YORK
SAN DIEGO
SAN FRANCISCO
SILICON VALLEY
WASHINGTON

DAVID J. SHAW
TEL 202.662.5094
FAX 202.778.5094
DSHAW @ COV.COM

September 18, 2012

VIA HAND DELIVERY

June Im, Esq.
Federal Trade Commission
Bureau of Competition
601 New Jersey Avenue, N.W.

[redacted]

Re: File No. 121-0062: ViroPharma

Dear June:

Please find enclosed responses, in part, to Specification 20, 21, 23, 28, and 35.

[redacted]

Viropharma's Responses to Specifications 2 of 2

manner by incorporates by reference each and every objection stated in the General Objections.

sions and to each individual deriv[illegible] consultant involved in the vaccine [illegible] Supp[illegible]

A. his/her role;



Confidential

[redacted]

[redacted]

cin FDA

SPECIFICATION 21: Identify ViroPharma's reason(s) for filing the Vanco
Submissions and submit all documents relating to your response.

Response:

gulatory

The Vancocin FDA

reactive to shifting FDA positions on bioequivalence standards or

specific FDA administrative actions (e.g., the convening of

meetings, the publication of guidance, and new information made

ViroPharma petitioned the FDA in order to gain significant scientific, legal, and re
issues that arose in connection with the FDA's consideration and adoption of new
bioequivalence standards for approving generic versions of Vancocin
Submissions were generally
generic versions of Vancoc
FDA reviewers and

FOIA litigation, from tests performed by ViroPharma, and from the scientific community

the FDA Submissions.

SPECIFICATION 23: Identify and describe any assessment ViroPharma made re

for such assessments, and submit all documents relating to your response.

Response:

submissions. ViroPharma will identify any further specific non-privileged

the Vancocin FDA S